Analysts Anticipate TG Therapeutics Inc (NASDAQ:TGTX) to Announce -$0.37 EPS

Brokerages expect TG Therapeutics Inc (NASDAQ:TGTX) to announce ($0.37) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for TG Therapeutics’ earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.30). The business is scheduled to announce its next quarterly earnings results on Tuesday, February 11th.

On average, analysts expect that TG Therapeutics will report full-year earnings of ($1.96) per share for the current fiscal year, with EPS estimates ranging from ($2.19) to ($1.83). For the next year, analysts anticipate that the company will report earnings of ($1.45) per share, with EPS estimates ranging from ($1.98) to ($0.76). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.33). The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 123,130.93% and a negative return on equity of 2,411.79%.

A number of research analysts have recently weighed in on TGTX shares. B. Riley assumed coverage on shares of TG Therapeutics in a research note on Wednesday, November 27th. They set a “buy” rating and a $12.00 price objective for the company. Zacks Investment Research lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. ValuEngine cut TG Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 21st. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of TG Therapeutics in a report on Tuesday, November 12th. Finally, BidaskClub raised TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $12.95.

Large investors have recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. lifted its stake in shares of TG Therapeutics by 2.5% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 609,374 shares of the biopharmaceutical company’s stock worth $5,271,000 after purchasing an additional 14,975 shares during the period. Swiss National Bank increased its stake in TG Therapeutics by 19.9% in the second quarter. Swiss National Bank now owns 140,500 shares of the biopharmaceutical company’s stock valued at $1,215,000 after purchasing an additional 23,300 shares during the last quarter. JPMorgan Chase & Co. increased its stake in TG Therapeutics by 12.7% in the second quarter. JPMorgan Chase & Co. now owns 258,296 shares of the biopharmaceutical company’s stock valued at $2,061,000 after purchasing an additional 29,098 shares during the last quarter. Bank of New York Mellon Corp increased its stake in TG Therapeutics by 10.5% in the second quarter. Bank of New York Mellon Corp now owns 311,004 shares of the biopharmaceutical company’s stock valued at $2,690,000 after purchasing an additional 29,627 shares during the last quarter. Finally, Artal Group S.A. lifted its position in TG Therapeutics by 12.5% during the second quarter. Artal Group S.A. now owns 900,000 shares of the biopharmaceutical company’s stock worth $7,785,000 after buying an additional 100,000 shares during the period. Institutional investors own 48.63% of the company’s stock.

Shares of NASDAQ TGTX opened at $7.12 on Friday. The firm’s 50-day moving average is $7.22 and its two-hundred day moving average is $6.94. TG Therapeutics has a 12-month low of $3.32 and a 12-month high of $9.38. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 2.77.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Read More: Profit margin is different from the revenue

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.